Free Press Releases Logo
 
You are arrow Home arrow News arrow Science and research arrow Covance launches pharmacokinetic service line
Quiz

Free Press Releases

Covance launches pharmacokinetic service line
Written by Shirley Scott   
Friday, 03 August 2007
Covance (Madison, Wisconsin) has begun offering pharmacokinetic studies using B-Clear, described as the only in-vitro method to predict in-vivo liver disposition.  The company licensed B-Clear from Qualyst (Raleigh, North Carolina), a specialist in ADMET (absorption, distribution, metabolism, excretion and toxicology) technology, in October 2006.  Terms of the deal were not disclosed.
Covance (Madison, Wisconsin) has begun offering pharmacokinetic studies using B-Clear, described as the only in-vitro method to predict in-vivo liver disposition.  The company licensed B-Clear from Qualyst (Raleigh, North Carolina), a specialist in ADMET (absorption, distribution, metabolism, excretion and toxicology) technology, in October 2006.  Terms of the deal were not disclosed.

 

B-Clear is a sandwich-cultured hepatocyte system that predicts hepatobiliary disposition, including hepatic uptake, hepatic accumulation, biliary clearance and drug transport.  It can be used as a screen for lead optimisation during drug discovery and to address drug transport questions during development.  It is said to enable better prediction of bioavailability, pharmacokinetics, species-specific drug dosing and candidate selection.

 

Covance will initially offer B-Clear-HU (primary human) and B-Clear-RT (primary rat) hepatocytes for hepatobiliary disposition and hepatic transport studies.  Services using non-human primate, canine and mouse hepatocytes are expected to become available in late 2007. Submitted by  www.jobs4dd.com E-mail : This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 
< Prev   Next >
7mistakes

Sponsored Links

ebook